Meshulami N, Tavolacci S, de Miguel-Perez D, Rolfo C, Mack PC, Hirsch FR
Clin Lung Cancer 2023 Jul;24(5):401-406. Epub 2023 Apr 25 doi: 10.1016/j.cllc.2023.03.014. PMID: 37208221

Clinical outcomes of EGFR-TKIs in advanced squamous cell lung cancer.

Si JF, Xiang J, Wei JW, Hao Y, Song ZB
Neoplasma 2022 Jul;69(4):976-982. Epub 2022 May 23 doi: 10.4149/neo_2022_220329N348. PMID: 35603955

Analysis of bevacizumab treatments and metastatic sites of lung cancer.

Sato H, Nagashima H, Akiyama M, Ito T, Hashimoto T, Saikawa H, Utsumi Y, Maemondo M
Cancer Treat Res Commun 2021;26:100290. Epub 2020 Dec 26 doi: 10.1016/j.ctarc.2020.100290. PMID: 33373900

A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).

Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, Herbst RS, Papadimitrakopoulou VA
Clin Lung Cancer 2021 May;22(3):170-177. Epub 2020 Oct 14 doi: 10.1016/j.cllc.2020.09.013. PMID: 33221175 Free PMC Article

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.

Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y
Lancet Oncol 2019 Nov;20(11):1506-1517. Epub 2019 Sep 30 doi: 10.1016/S1470-2045(19)30626-6. PMID: 31582355

See all (67)

Diagnosis

Large-cell Neuroendocrine Carcinoma of the Lung with Carcinoid Syndrome.

Yamamoto M, Ito R, Tsujibata A, Morita H, Yoneda T, Matano Y, Higashikata T
Intern Med 2023 May 15;62(10):1557-1563. Epub 2022 Oct 5 doi: 10.2169/internalmedicine.0099-22. PMID: 36198589 Free PMC Article

Bullous pemphigoid associated with squamous cell lung carcinoma showing remarkable response to carboplatin-based chemotherapy: a case report.

Shrestha P, George MK, Baidya S, Rai SK
J Med Case Rep 2022 May 5;16(1):184. doi: 10.1186/s13256-022-03323-9. PMID: 35513831 Free PMC Article

NUT carcinoma of the lung.

Lantuejoul S, Pissaloux D, Ferretti GR, McLeer A
Semin Diagn Pathol 2021 Sep;38(5):72-82. Epub 2021 Jun 16 doi: 10.1053/j.semdp.2021.06.005. PMID: 34176698

Metastatic model of HPV+ oropharyngeal squamous cell carcinoma demonstrates heterogeneity in tumor metastasis.

Vermeer DW, Coppock JD, Zeng E, Lee KM, Spanos WC, Onken MD, Uppaluri R, Lee JH, Vermeer PD
Oncotarget 2016 Apr 26;7(17):24194-207. doi: 10.18632/oncotarget.8254. PMID: 27013584 Free PMC Article

Emphasizing on heat shock protein 90's utility in head and neck squamous cell carcinoma treatment.

Routray S, Sunkavalli A, Swain N, Shankar AA
J Cancer Res Ther 2013 Oct-Dec;9(4):583-6. doi: 10.4103/0973-1482.126451. PMID: 24518700

See all (54)

Therapy

PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells.

Exposito F, Redrado M, Houry M, Hastings K, Molero-Abraham M, Lozano T, Solorzano JL, Sanz-Ortega J, Adradas V, Amat R, Redin E, Leon S, Legarra N, Garcia J, Serrano D, Valencia K, Robles-Oteiza C, Foggetti G, Otegui N, Felip E, Lasarte JJ, Paz-Ares L, Zugazagoitia J, Politi K, Montuenga L, Calvo A
Cancer Res 2023 Aug 1;83(15):2513-2526. doi: 10.1158/0008-5472.CAN-22-3023. PMID: 37311042

A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).

Camrelizumab: First Global Approval.

Markham A, Keam SJ
Drugs 2019 Aug;79(12):1355-1361. doi: 10.1007/s40265-019-01167-0. PMID: 31313098

Immunotherapy for Advanced Lung Cancer.

Asmar R, Rizvi NA
Cancer J 2015 Sep-Oct;21(5):383-91. doi: 10.1097/PPO.0000000000000151. PMID: 26389763

See all (140)

Prognosis

Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology?

Meshulami N, Tavolacci S, de Miguel-Perez D, Rolfo C, Mack PC, Hirsch FR
Clin Lung Cancer 2023 Jul;24(5):401-406. Epub 2023 Apr 25 doi: 10.1016/j.cllc.2023.03.014. PMID: 37208221

NUT carcinoma of the lung.

Lantuejoul S, Pissaloux D, Ferretti GR, McLeer A
Semin Diagn Pathol 2021 Sep;38(5):72-82. Epub 2021 Jun 16 doi: 10.1053/j.semdp.2021.06.005. PMID: 34176698

Analysis of bevacizumab treatments and metastatic sites of lung cancer.

Sato H, Nagashima H, Akiyama M, Ito T, Hashimoto T, Saikawa H, Utsumi Y, Maemondo M
Cancer Treat Res Commun 2021;26:100290. Epub 2020 Dec 26 doi: 10.1016/j.ctarc.2020.100290. PMID: 33373900

A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).

Immunotherapy for Advanced Lung Cancer.

Asmar R, Rizvi NA
Cancer J 2015 Sep-Oct;21(5):383-91. doi: 10.1097/PPO.0000000000000151. PMID: 26389763

See all (76)

Clinical prediction guides

PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells.

NUT carcinoma of the lung.

Lantuejoul S, Pissaloux D, Ferretti GR, McLeer A
Semin Diagn Pathol 2021 Sep;38(5):72-82. Epub 2021 Jun 16 doi: 10.1053/j.semdp.2021.06.005. PMID: 34176698

A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).

ΔNp63 in squamous cell carcinoma: defining the oncogenic routes affecting epigenetic landscape and tumour microenvironment.

Gatti V, Fierro C, Annicchiarico-Petruzzelli M, Melino G, Peschiaroli A
Mol Oncol 2019 May;13(5):981-1001. Epub 2019 Mar 22 doi: 10.1002/1878-0261.12473. PMID: 30845357 Free PMC Article

Immunotherapy for Advanced Lung Cancer.

Asmar R, Rizvi NA
Cancer J 2015 Sep-Oct;21(5):383-91. doi: 10.1097/PPO.0000000000000151. PMID: 26389763

See all (58)